Cisplatin News and Research

RSS

Adding veliparib to chemotherapy can extend progression-free survival in patients with “BRCA-like” breast cancer

Results from the SWOG S1416 clinical trial show that adding veliparib to chemotherapy can significantly extend progression-free survival (PFS) times in patients with triple-negative breast cancer (TNBC) that has a "BRCA-like" phenotype.

31 Jan 2023

Pembrolizumab offers major added survival benefit for patients with advanced cervical cancer

Pembrolizumab has recently been approved in combination with chemotherapy for the treatment of women with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1. Chemotherapy with or without bevacizumab is possible.

25 Jan 2023

Targeting newly discovered signaling pathway could boost the potency of cancer therapeutics

Cells zealously protect the integrity of their genomes, because damage can lead to cancer or cell death. The genome -; a cell's complete set of DNA -; is most vulnerable while it is being duplicated before a cell divides. Cancer cells constantly are dividing, so their genomes are constantly in jeopardy.

24 Jan 2023

Addition of nab-paclitaxel to gemcitabine/cisplatin does not improve overall survival of patients with advanced biliary tract cancers

Adding nab-paclitaxel to a standard treatment of gemcitabine plus cisplatin does not significantly extend median overall survival (OS) time for patients with advanced biliary tract cancers, although it may provide a benefit for subsets of patients with locally advanced disease or gallbladder adenocarcinoma.

20 Jan 2023

Wayne State researcher wins $1.7 million NIH award to understand and tackle cisplatin-induced ototoxicity

A Wayne State University researcher has received a $1.7 million, five-year award from the National Institute on Deafness and Other Communication Disorders of the National Institutes of Health for the study, "Targeting nitrative stress for treatment of cisplatin ototoxicity."

5 Jan 2023

New combination of drugs may lead to improved treatment of cervical cancer

A new combination of drugs slowed the growth of cancer cells by an unexpected mechanism that may one day lead to improved treatment of cervical cancer, a UT Southwestern-led study published in Molecular Cancer Research suggests.

19 Dec 2022

Researchers develop transgenic mice with the FRET biosensor for in vivo observation of necroptosis

Necroptosis is a form of regulated cell death (RCD) similar to apoptosis, the most commonly studied type of RCD. In contrast to apoptosis, plasma membrane rupture in necroptotic cells occurs at early time points.

9 Dec 2022

Existing drug may help decrease side effects of widely used cancer treatment

A Michigan State University researcher is part of an international team that found an existing drug may help decrease side effects of cisplatin, a widely used cancer treatment that was discovered at MSU in 1965.

30 Nov 2022

Pt(IV)-conjugated drug-delivery system shows efficacy in glioblastoma therapy

A recent study demonstrated a novel method for delivering anti-cancer drugs, conjugated to modified cell-penetrating peptides across the blood-brain barrier, in mice to treat glioblastoma.

18 Nov 2022

New drug could be a game changer for cancer patients undergoing chemotherapy

Cisplatin is a chemotherapy indicated to fight tumors in many types of cancer. However, it does have major side effects – especially kidney toxicity, that can lead to acute kidney failure.

15 Nov 2022

Researchers identify gene expression correlated with response to chemotherapy in medulloblastomas

An international team led by the Department of Neurosurgery, Niigata University, has identified a new gene called Schlafen11 (SLFN11) whose expression is tightly correlated with response to chemotherapy in medulloblastomas, a highly malignant brain tumor affecting pediatric, adolescent, and young adult populations.

7 Nov 2022

Research shows how a very low dose of rhenium metal complex kills ovarian cancer cells

Metal-containing complexes have taken up center stage in the search for new cancer drugs that are as free of side effects as possible.

12 Oct 2022

Metal compounds could be the solution for drug-resistant fungal infections

University of Queensland researchers say metal compounds could be the answer to the growing problem of drug-resistant fungal infections.

26 Sep 2022

Chemical compounds containing special metals can fight fungal infections

An international collaboration led by researchers from the University of Bern and the University of Queensland in Australia has demonstrated that chemical compounds containing special metals are highly effective in fighting dangerous fungal infections.

23 Sep 2022

First-of-its-kind messenger RNA therapy developed for ovarian cancer, cachexia

Researchers at Oregon State University and Oregon Health & Science University have developed a promising, first-of-its-kind messenger RNA therapy for ovarian cancer as well as cachexia, a muscle-wasting condition associated with cancer and other chronic illnesses.

13 Sep 2022

MSK researchers reveal a promising treatment option for bladder cancer patients

Researchers from Memorial Sloan Kettering Cancer Center (MSK) shared a promising treatment option for bladder cancer patients today at The European Society for Medical Oncology (ESMO) Congress 2022.

13 Sep 2022

Nivolumab approved for combination with fluoropyrimidine- and platinum-based combination chemotherapy

Nivolumab has recently been approved both in combination with fluoropyrimidine- and platinum-based combination chemotherapy and in combination with ipilimumab for the first-line treatment of adults with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma with PD-L1 expression of at least one percent. The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in two early benefit assessments whether these two combinations have an added benefit for patients in comparison with chemotherapy alone.

8 Aug 2022

Researchers discover a ‘weak spot’ that makes multi-drug resistant tumors vulnerable

One of the greatest challenges facing cancer researchers is to understand why some patients don't respond to treatments.

22 Jul 2022

Biochemist finds new way to protect healthy leukocytes during chemotherapy

A biochemist from RUDN and IBMC has found a way to protect healthy leukocytes during leukemia chemotherapy. Small nitrogen-containing polyamine molecules give the necessary protection.

14 Jul 2022

Clinical trial examining the combination of atezolizumab and chemoradiation for patients with limited-stage SCLC reaches accrual

The NRG Oncology/Alliance clinical trial NRG-LU005, examining the addition of the immunotherapy drug atezolizumab combined with chemoradiation for patients with limited-stage small cell lung cancer (SCLC) recently reached the trial's accrual goal of 506 patients.

8 Jul 2022